161 related articles for article (PubMed ID: 38162437)
1. Lipid-lowering therapy and LDL-C control for primary prevention in persons with diabetes across 90 health systems in the United States.
Decicco E; Peterson ED; Gupta A; Khalaf Gillard K; Sarnes E; Navar AM
Am J Prev Cardiol; 2023 Dec; 16():100604. PubMed ID: 38162437
[TBL] [Abstract][Full Text] [Related]
2. Gaps in Guideline-Based Lipid-Lowering Therapy for Secondary Prevention in the United States: A Retrospective Cohort Study of 322 153 Patients.
Navar AM; Kolkailah AA; Gupta A; Gillard KK; Israel MK; Wang Y; Peterson ED
Circ Cardiovasc Qual Outcomes; 2023 Aug; 16(8):533-543. PubMed ID: 37529931
[TBL] [Abstract][Full Text] [Related]
3. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
[TBL] [Abstract][Full Text] [Related]
4. Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial.
Lee SJ; Cha JJ; Choi WG; Lee WS; Jeong JO; Choi S; Cho YH; Park W; Yoon CH; Lee YJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Hong SJ; Kim JS;
JAMA Cardiol; 2023 Sep; 8(9):853-858. PubMed ID: 37531130
[TBL] [Abstract][Full Text] [Related]
5. Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002-2016.
Romanelli RJ; Ito MK; Karalis DG; Huang HC; Iorga ŞR; Kam IW; Thompson S; Azar KMJ
J Clin Lipidol; 2020; 14(3):305-314. PubMed ID: 32362513
[TBL] [Abstract][Full Text] [Related]
6. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
7. Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients.
Chen CC; Rane PB; Hines DM; Patel J; Harrison DJ; Wade RL
Ther Clin Risk Manag; 2018; 14():2425-2435. PubMed ID: 30587999
[TBL] [Abstract][Full Text] [Related]
8. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
[TBL] [Abstract][Full Text] [Related]
9. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, treatment, and control of severe hyperlipidemia.
Gold ME; Nanna MG; Doerfler SM; Schibler T; Wojdyla D; Peterson ED; Navar AM
Am J Prev Cardiol; 2020 Sep; 3():100079. PubMed ID: 34327462
[TBL] [Abstract][Full Text] [Related]
11. Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i.
Mackinnon ES; Har B; Champsi S; Wani RJ; Geyer L; Shaw E; Farris MS; Anderson TJ
Cardiol Ther; 2023 Jun; 12(2):327-338. PubMed ID: 36656500
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
Morieri ML; Avogaro A; Fadini GP;
Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
[TBL] [Abstract][Full Text] [Related]
13. Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial.
Lee B; Hong SJ; Rha SW; Heo JH; Hur SH; Choi HH; Kim KJ; Kim JH; Kim HK; Kim U; Choi YJ; Lee YJ; Lee SJ; Ahn CM; Ko YG; Kim BK; Choi D; Hong MK; Jang Y; Kim JS
Atherosclerosis; 2023 Dec; 386():117373. PubMed ID: 37995599
[TBL] [Abstract][Full Text] [Related]
14. Adding ezetimibe to statin therapy: latest evidence and clinical implications.
Vavlukis M; Vavlukis A
Drugs Context; 2018; 7():212534. PubMed ID: 30023003
[TBL] [Abstract][Full Text] [Related]
15. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
[TBL] [Abstract][Full Text] [Related]
16. Lipid-Lowering Therapy Utilization and Dosage Among Patients with Acute Coronary Syndrome Events: A Retrospective Cohort from 12 Community Hospitals.
Khatib R; Yeh EJ; Glowacki N; McGuiness CB; Xie H; Wade RL; Kalich BA; Li Y; Rifai A; Sawlani N
Clin Epidemiol; 2023; 15():547-557. PubMed ID: 37168051
[TBL] [Abstract][Full Text] [Related]
17. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide.
Pokharel Y; Tang F; Jones PG; Nambi V; Bittner VA; Hira RS; Nasir K; Chan PS; Maddox TM; Oetgen WJ; Heidenreich PA; Borden WB; Spertus JA; Petersen LA; Ballantyne CM; Virani SS
JAMA Cardiol; 2017 Apr; 2(4):361-369. PubMed ID: 28249067
[TBL] [Abstract][Full Text] [Related]
18. The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Jamialahmadi T; Baratzadeh F; Reiner Ž; Simental-Mendía LE; Xu S; Susekov AV; Santos RD; Sahebkar A
Mediators Inflamm; 2021; 2021():9661752. PubMed ID: 34526854
[TBL] [Abstract][Full Text] [Related]
19. Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients.
Okerson T; Patel J; DiMario S; Burton T; Seare J; Harrison DJ
J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28314797
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
